A GLOBAL pharmaceutical firm is pulling out of Edinburgh with the expected loss of 13 jobs.
AstraZeneca’s Capital offices, operating from Lochside Avenue, centred on clinical research trials and is understood to have been integral to the development of breast cancer drug Tamoxifen, among other products.
It is understood the city branch was the company’s main clinical testing base and had been in business for the last 35 years.
An AstraZeneca worker, who asked not to be named, said: “I think it’s very sad for Scotland to lose a key pharmaceutical company,the last of the blue chip pharmaceutical companies”.
A spokesperson for the firm said: “AstraZeneca remains committed to continuing its clinical research activities in Scotland and the UK. We will continue to have field-based employees located in Scotland.”